8 Chicago area hospitals acquired by California-based healthcare system
Prime Healthcare, a California-based national health care system, said it acquired eight Chicago-area hospitals.
The national system also said it will take over multiple senior living and care facilities in Chicago and surrounding suburbs.
Prime Healthcare promised millions of dollars of investments into improving and upgrading the facilities.
A California-based healthcare company officially acquired eight hospitals and multiple senior living and care facilities in the Chicago area.
Prime Healthcare, which already operates hospitals and other facilities in 14 states, announced the acquisition on Saturday.
What we know
The Illinois Health Facilities and Services Review Board approved the acquisition after an extensive review process.
After taking over the Chicago area hospitals and other facilities, Prime Healthcare now operates 51 hospitals, more than 360 outpatient locations and oversees nearly 57,000 employees and affiliated physicians.
The system touted its high rankings for health care and track record of turning around financially struggling hospitals.
Prime Healthcare said it made employment offers to "substantially all associates at the Chicago area facilities it acquired. The company also said it's committed $250 million for facility upgrades, capital improvements and technology and systems upgrades.
Prime Healthcare will now oversee the following hospitals:
Holy Family Medical Center in Des Plaines
Mercy Medical Center in Aurora
Resurrection Medical Center in Chicago
Saint Francis Hospital in Evanston
Saint Joseph Medical Center in Joliet
Saint Joseph Hospital in Elgin
St. Mary's Hospital in Kankakee
Saint May of Nazareth Hospital in Chicago
Prime Healthcare will also take over several home health and senior living facilities:
Fox Knoll Village in Aurora
Villa Franciscan Place in Joliet
Heritage Village and Heritage Lodge in Kankakee
Resurrection Place in Park Ridge
Rainbow Hospice in Chicago
Ascension at Home Illinois in Joliet
Ascension at Home Illinois in Kankakee
The system also said it will preserve charity care programs and the hospitals' affiliation with the Catholic church.
What they're saying
Local officials praised the deal for Prime Healthcare to take over the hospitals and facilities in Chicago and throughout the suburbs.
"This transition marks a significant moment in our community, but I want to make it clear: the quality of care our residents rely on will not be compromised," said Chicago Ald. Daniel La Spata (1st Ward) in a statement. "Prime Healthcare has committed to not only maintaining but enhancing the services at Saint Mary Hospital, ensuring that our neighborhood continues to have access to top-tier medical care."
State Rep. Eva-Dina Delgado (D-Chicago) also praised the acquisition.
"This acquisition represents an opportunity for our community to benefit from Prime Healthcare's commitment to compassionate, high-quality care," said Delgado, in a statement "I am looking forward to seeing the positive impact this transition will bring to our neighborhoods, from preserving critical healthcare services to creating new opportunities for healthcare professionals."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Intel earnings, Paramount-Skydance deal, Tesla rises
Here are some of the stories Wall Street is watching on Friday, July 25. Shares of Intel (INTC) are falling after posting a Q2 loss, though revenue topped estimates. The FCC has approved the $8 billion merger between Paramount (PARA, PARAA) and Skydance. Tesla (TSLA) shares are rising on a Business Insider report that the company plans to launch its robotaxi service in San Francisco this weekend. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. It's time for Yahoo! Finance's market minute. Stocks are higher today as the major averages look to close out a strong week of gains amid earnings and trade updates. The S&P 500 now closing out its 13th record high in Thursday's trading session. Meanwhile, Intel shares are falling today after the chipmaker said it would slash founder costs and its latest attempt to turn around its struggling business. Concerns about where that leaves Intel's chip business and manufacturing overshadowed by a better than expected earnings report. Plus, Paramount and Skydance's $8 billion deal has been approved by the FCC. The deal, which was announced more than a year ago, includes the CBS broadcast television network, Paramount Pictures, and the Nickelodeon channel. Paramount chair, Sherry Redstone, is set to depart the company's board once the Skydance merger is complete. And Tesla shares are on the rise today as the company is reported to launch its robo taxis in San Francisco this weekend. That's according to Insider. Unlike its Austin debut, the robo taxis will use safety drivers seated in the cars. And that's your Yahoo! Finance market minute. Scan the QR code below to track the best and worst performing stocks of the trading session. Related Videos Japan's 'novel' US investment deal faces 'a lot' of questions Palantir highs, Phillips 66 Q2 beat, Comcast's Versant spin-off Question of the day: Are we in a market bubble? What Volkswagen's $1.5B tariff hit means for US expansion Sign in to access your portfolio
Yahoo
16 minutes ago
- Yahoo
Edwards Lifesciences Lifts 2025 Outlook On Strong First Half Performance
Edwards Lifesciences' (NYSE:EW) stock surged Friday following a strong second-quarter 2025 earnings report that saw the medical device innovator surpass revenue and earnings expectations, driven by significant growth across its heart valve therapies. The strong performance prompted the company to raise its full-year sales guidance, signaling renewed momentum in its core markets. The heart devices company reported sales of $1.53 billion on Thursday after hours, beating the consensus of $1.49 billion and within the management guidance of $1.45 billion-$1.53 billion. Sales grew 11.9% or 10.6% adjusted, with strength across all product groups. Edwards Lifesciences reported adjusted earnings of 67 cents, beating the consensus of 62 cents and the management guidance of 59-65 cents per company reported Transcatheter Aortic Valve Replacement (TAVR) sales of $1.1 billion, marking an increase of 8.9% (or 7.8% on a constant currency basis). The company said that TAVR growth for the quarter surpassed their expectations. Transcatheter Mitral and Tricuspid Therapies (TMTT) segments achieved second-quarter sales of $134.5 million, demonstrating a year-over-year growth of 61.9%, or more than 57.1% on a constant currency basis. In the Surgical segment, second-quarter global sales reached $267 million, an increase of 7.7% over the prior year, or 6.8% on a constant currency basis. Outlook 'We are pleased to report strong second quarter results that delivered double-digit sales growth. Based on our better-than-expected first half performance and the many catalysts across our portfolio, we are confident in our full-year outlook and are raising our sales and EPS guidance,' said Bernard Zovighian, CEO. Edwards Lifesciences raised its 2025 sales guidance from $5.70 billion-$6.10 billion to $5.90 billion-$6.10 billion compared to the consensus of $5.91 billion. The company affirms fiscal 2025 adjusted earnings guidance of $2.40-$2.50 per share compared to the consensus of $2.48. Edwards Lifesciences forecasts third-quarter adjusted earnings of 54-60 cents, compared to the consensus of 60 cents, and sales of $1.46 billion, $1.54 billion versus the consensus of $1.48 billion. View more earnings on EW The company is increasing its underlying growth rate guidance for TAVR to 6% to 7%, driven by strong performance, and its sales guidance range for TAVR to $4.3 billion to $4.5 billion. Sales guidance for TMTT and Surgical product groups remains unchanged. Analyst Insights: Goldman Sachs Goldman Sachs said Friday that the second quarter of 2025 marked a key turning point for the company and reinforced its belief that Edwards is on track to achieve steady double-digit revenue growth again. The firm noted that Edwards' core TAVR business is gaining momentum, even though the quarter only partially reflected the impact of the new asymptomatic indication and included just a small boost from Boston Scientific Corporation's (NYSE:BSX) planned market exit. This gives Goldman confidence that the business will operate at a stronger baseline. Analyst David Roman expects Edwards to get back to its previous strong performance over the next few years, with revenue growing over 10% and operating margins above 30%. With this kind of growth, Goldman Sachs believes the stock deserves a higher valuation, more than 30 times its earnings. The analyst maintains the Buy rating, raising the price forecast from $89 to $101. Other Analysts Several leading financial analysts re-evaluated their outlook on Edwards Lifesciences, with a general trend toward increased price forecasts. Baird has maintained a Neutral rating on the company, slightly increasing its price forecast from $78 to $79. Deutsche Bank, on the other hand, reiterates a Buy rating and has significantly raised its price forecast from $85 to $94. Evercore ISI affirms an In-Line rating, with a modest increase in its price forecast from $77 to $80. Wells Fargo continues to maintain an Overweight rating, raising its price forecast from $80 to $84. Similarly, RBC Capital maintains an Outperform rating, lifting its price forecast from $85 to $89. Piper Sandler also keeps an Overweight rating, increasing its price target from $83 to $90. Barclays maintains an Overweight rating and has raised its price forecast from $90 to $95. Finally, a Stifel analyst has reiterated a Buy rating, also increasing the price forecast from $90 to $95. Price Action: EW stock is trading higher by 4.87% to $79.49 at last check Friday. Read Next:Image via Shutterstock Latest Ratings for EW Date Firm Action From To Feb 2022 UBS Upgrades Neutral Buy Jan 2022 Morgan Stanley Maintains Overweight Jan 2022 Raymond James Maintains Outperform View More Analyst Ratings for EW View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? EDWARDS LIFESCIENCES (EW): Free Stock Analysis Report This article Edwards Lifesciences Lifts 2025 Outlook On Strong First Half Performance originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Why Advanced Micro Devices (AMD) Shares Are Climbing Today
Advanced Micro Devices (NASDAQ:AMD) shares climbed about 3% Friday after analysts flagged Intel's (NASDAQ:INTC) ongoing market?share losses to AMD. That's why investor confidence rose on expectations that AMD keeps grabbing business from its larger rival. Warning! GuruFocus has detected 5 Warning Signs with AMD. J.P. Morgan analysts noted Intel's shift toward a more fabless model won't pay off for another 1824 months, leaving AMD to reinforce its position with Ryzen and EPYC platforms. They see sustained momentum in AMD's server?CPU shipments as cloud providers and enterprises favor its cost?efficient designs. Morgan Stanley chimed in, pointing to Intel's margin pressures from startup costs and restructuring charges. That contrast boosts AMD's near?term outlook: its higher gross margins and leaner expense base paint a more resilient picture. Market watchers also highlight AMD's expanding GPU lineup as a secondary growth driver, with generative?AI workloads fueling demand alongside NVIDIA (NASDAQ:NVDA). As Intel grapples with transition costs, AMD stands to pick up share in both PC and data?center markets. With analysts' price targets generally above current levels, AMD's stock rally underscores a broader semiconductor shift, smaller players seizing ground as incumbents navigate costly transformations. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
